BioHarvest Sciences Announces New Strategic Hires for CDMO Services Business Unit
BioHarvest Sciences Announces New Strategic Hires for CDMO Services Business Unit
Management Adding Critical Leadership Roles to Support Growth of Recently Launched CDMO Business Unit
管理層增加關鍵領導職位以支持最近成立的CDMO業務部門的增長
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 13, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the appointment of two senior hires in the areas of business development and science to spearhead key initiatives as part of the Company's recently launched CDMO Services Business Unit.
不列顛哥倫比亞省溫哥華和以色列雷霍沃特--(Newsfile Corp.,2024年3月13日)——開創其專利植物合成技術平台的生物技術公司BioHarvest Sciences Inc.(CSE:BHSC)(OTCQB:CNVCF)(“BioHarvest” 或 “公司”)今天宣佈任命兩名業務發展和科學領域的高級員工,以領導公司最近的一項關鍵舉措成立了 CDMO 服務業務部。
"Our new CDMO Services division is such a natural complement to the core competencies we've developed in our Molecular Research and Product development teams," commented BioHarvest CEO Ilan Sobel, adding "but even with these powerful existing synergies, we needed to add leaders with specific skill sets in order to accelerate growth on both commercial and scientific levels to capitalize on major opportunities ahead."
BioHarvest首席執行官伊蘭·索貝爾評論說:“我們新的CDMO服務部門是對我們在分子研究和產品開發團隊中開發的核心能力的自然補充,但即使有這些強大的現有協同效應,我們也需要增加具有特定技能的領導者,以加速商業和科學層面的增長,以抓住未來的重大機遇。”
Matt Zrebiec has been appointed as VP of Business Development - with a focus on sourcing and closing new deals for the CDMO Business Unit. Matt leverages 23 years of experience in the branded specialty, biotech, generics, and CDMO pharmaceutical sector. He previously served in leadership roles at Teva, Wyeth Vaccines, Par Endo, Lupin, Hikma, and Piramal Pharma. He pulls on a deep expertise in business development & licensing, corporate development, M&A, analytics modeling, portfolio strategy, CDMO lead gen, API sales, and life cycle management. Matt has managed large teams and delivered complex deals, creating significant value for his prior organizations.
馬特·茲雷比克被任命爲業務發展副總裁,主要負責爲CDMO業務部門尋找和完成新交易。Matt 在品牌專業、生物技術、仿製藥和 CDMO 製藥領域擁有 23 年的經驗。他之前曾在梯華、惠氏疫苗、遠藤百樂、盧平、Hikma和Piramal Pharma擔任領導職務。他在業務開發和許可、企業發展、併購、分析建模、投資組合策略、CDMO潛在客戶、API銷售和生命週期管理方面擁有深厚的專業知識。Matt 管理過大型團隊並交付了複雜的交易,爲他以前的組織創造了巨大的價值。
Professor Itay Mayrose has been appointed as a Senior Artifical Intelligence (AI) Scientist, spearheading development initiatives as part of the CDMO Business Unit. Professor Itay Mayrose is a globally recognized expert in plant computational genomics, renowned for his multidisciplinary approach that merges computer science with biological research. His research encompasses multiple fields, spanning genomics, molecular biology, ecology, and phylogenetics. Professor Mayrose pioneered the use of artificial intelligence into genome editing and evolutionary studies, leading to groundbreaking discoveries. Research led by his team was published in the most prestigious scientific journals, including Nature, Science, Nature Plants, Nature Ecology & Evolution, and Nature Communications.
伊泰·梅羅斯教授被任命爲高級人工智能(AI)科學家,作爲CDMO業務部門的一部分,領導開發計劃。伊泰·梅羅斯教授是全球公認的植物計算基因組學專家,以其將計算機科學與生物研究融爲一體的多學科方法而聞名。他的研究涵蓋多個領域,涵蓋基因組學、分子生物學、生態學和系統發育學。梅羅斯教授率先將人工智能應用於基因組編輯和進化研究,取得了開創性的發現。他的團隊領導的研究發表在最負盛名的科學期刊上,包括《自然》、《科學》、《自然植物》、《自然生態與進化》和《自然通訊》。
Dr. Zaki Rakib, Chairman of BioHarvest & President of the CDMO Services Business Unit, added: "I am pleased to welcome Matt Zrebiec and Professor Itay Mayrose to the BioHarvest Sciences team, where they will play a key role in driving forward the momentum of our recently launched CDMO Services Business Unit. Our CDMO division lies at the intersection of biology and mathematics, and with Dr. Itay's guidance, we can apply AI algorithms for machine learning, helping to accelerate the molecule development process. On the commercial side, we are gaining momentum and have several exciting CDMO partnership opportunities in our deal pipeline. I look forward to working with the team to close new deals, further expanding our reach into the pharma, cosmetics and nutrition industries."
BioHarvest董事長兼CDMO服務業務部總裁扎基·拉基布博士補充說:“我很高興歡迎馬特·茲雷比克和伊泰·梅羅斯教授加入BioHarvest Sciences團隊,他們將在推動我們最近成立的CDMO服務業務部門的勢頭方面發揮關鍵作用。我們的CDMO部門位於生物學和數學的交匯處,在Itay博士的指導下,我們可以將人工智能算法應用於機器學習,從而幫助加快分子開發過程。在商業方面,我們的發展勢頭增強,我們的交易中還有幾個令人興奮的CDMO合作機會。我期待與該團隊合作達成新交易,進一步將我們的業務範圍擴大到製藥、化妝品和營養品行業。”
BioHarvest CDMO Corporate Update Webinar - Wednesday March 13, 2024, 2:30 PM EST
BioHarvest CDMO 企業最新動態網絡研討會——美國東部標準時間 2024 年 3 月 13 日星期三下午 2:30
CEO Ilan Sobel and Chairman Zaki Rakib will host the call at 2:30 p.m. Eastern time on Wednesday, March 13, 2024, with a formal presentation to discuss the launch of the CDMO business unit, provide a corporate update and conclude with a question-and-answer session. To participate, all interested media and investors are invited to pre-register.
首席執行官伊蘭·索貝爾和董事長扎基·拉基布將於美國東部時間2024年3月13日星期三下午 2:30 主持電話會議,並進行正式演講,討論CDMO業務部門的啓動,提供公司最新情況,並以問答環節結束。要參與,邀請所有感興趣的媒體和投資者進行預登記。
Registration link:
註冊鏈接:
About BioHarvest Sciences Inc.
BioHarvest 科學公司簡介
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit .
BioHarvest Sciences Inc.(CSE:BHSC)(場外交易代碼:CNVCF)(FSE:8MV)是植物合成領域的領導者,利用其專利技術工藝培育植物基分子,無需種植底層植物。BioHarvest正在利用其植物合成技術在兩個主要垂直業務領域開發基於科學且經過臨床驗證的下一代治療解決方案;作爲代表尋求複雜分子的客戶的合同開發和生產組織(CDMO),以及作爲專有營養保健品健康和保健產品(包括膳食補充劑)的創造者。要了解更多信息,請訪問。
Forward-Looking Statements
前瞻性陳述
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
本新聞稿中提供的信息可能包括基於管理層當前估計、信念、意圖和預期的前瞻性陳述,並且存在許多風險和不確定性,這些風險和不確定性可能導致實際業績與前瞻性陳述中描述的結果存在重大差異。無法保證未來會有額外的合同。所有前瞻性陳述本質上都是不確定的,實際結果可能會受到我們無法控制的許多重大因素的影響。讀者不應過分依賴前瞻性陳述。除了通過我們的定期管理層討論和分析披露外,BHSC無意更新前瞻性陳述披露。
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其監管服務提供商均不對本新聞稿的充分性或準確性承擔責任。
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.
本新聞稿已由投資者關係副總裁戴夫·瑞安審查和批准,他對其內容承擔責任。
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
(604) 622-1186
info@bioharvest.com
BioHarvest 公司聯繫方式
投資者關係副總裁兼董事戴夫·瑞安
(604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
BHSC@mzgroup.us
投資者關係聯繫人:
盧卡斯·A·齊默爾曼
董事總經理
MZ 集團-MZ 北美
(949) 259-4987
BHSC@mzgroup.us